Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer
NCT ID: NCT02643407
Last Updated: 2015-12-31
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE3
Total Enrollment
488 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-10-31
Study Completion Date
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To compare the efficacy and safety of docetaxel plus nedaplatin with docetaxel plus cisplatin in managment of advanced/relapsed squamous cell lung cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is prospective to evaluate whether the efficacy and safety of docetaxel plus nedaplatin is non-inferior to docetaxel plus cisplatin in managment of advanced/relapsed squamous cell lung cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non-Small Cell Lung Cancer
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
squamous cell carcinoma
nedaplatin
cisplatin
docetaxel
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Docetaxel plus Nedaplatin
docetaxel 60mg/m2 and nedaplatin 80mg/m2, d1 every 3 weeks
Group Type
EXPERIMENTAL
Docetaxel
Intervention Type
DRUG
60mg/m2
Nedaplatin
Intervention Type
DRUG
80mg/m2
Docetaxel plus Cisplatin
docetaxel 60mg/m2 and cisplatin 75mg/m2, d1 every 3 weeks
Group Type
ACTIVE_COMPARATOR
Docetaxel
Intervention Type
DRUG
60mg/m2
Cisplatin
Intervention Type
DRUG
75mg/m2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Docetaxel
60mg/m2
Intervention Type
DRUG
Nedaplatin
80mg/m2
Intervention Type
DRUG
Cisplatin
75mg/m2
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients were required to be between 18 to 75 years, with histologically or cytologically proven squamous cell carcinoma of the lung, stage ⅢB (unfit for definitive radiotherapy), stage Ⅳ or relapsing;
2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero or one;
3. life expectancy \> 3 months;
4. No previous history of malignancy (except adequately treated carcinoma-in-situ of the cervix or basal cell carcinoma of the skin or superficial bladder cancer \[Ta, Tis \& T1\]); previously untreated with chemotherapy (eg. gemcitabine, platinum, paclitaxel); no previously systemic therapy on locally advanced and metastatic disease; patients were eligible for participation in the study if they had recurrence or metastasis and became locally advanced or metastatic lung cancer after 12 months treatment with gemcitabine, platinum or paclitaxel regimen in adjuvant or neoadjuvant chemotherapy;
5. Adequate organ function was required, as evidenced by absolute neutrophil count ≥ 1.5 x 109 /L, platelet count ≥ 100 x109/L, hemoglobin ≥ 90 g/L (9 g/dL);
6. hepatic enzyme levels ≤ 2.5 x the upper limit of the normal range (ULN), alkaline phosphatase levels ≤ 5.0 x the ULN, total bilirubin levels ≤ 1.5 x the ULN, and serum creatinine levels ≤1.5 mg/dL (or creatinine clearance ≥50 mL/min);
7. Previous radiotherapy was allowed if it involved \<25% of bone marrow and was completed 4 weeks before study entry; Patients must be recovered from acute toxicity before the clinical trials;
8. Pregnancy test: negative (female only); Women with fertility need pregnancy test (serum or urine) in 7 days before entering the group and the results were negative. Male or female patients with reproduction potential had to use an approved contraceptive method during and for 8 weeks after the end of study treatment.
9. Patients are judged by researcher to be the compliance of research requirements and follow-up.
10. All the patients provided their written informed consent before enrollment.
11. The standard first-line platinum-based regimens according to the clinical practice, and the efficacy was evaluated every two cycles.
2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero or one;
3. life expectancy \> 3 months;
4. No previous history of malignancy (except adequately treated carcinoma-in-situ of the cervix or basal cell carcinoma of the skin or superficial bladder cancer \[Ta, Tis \& T1\]); previously untreated with chemotherapy (eg. gemcitabine, platinum, paclitaxel); no previously systemic therapy on locally advanced and metastatic disease; patients were eligible for participation in the study if they had recurrence or metastasis and became locally advanced or metastatic lung cancer after 12 months treatment with gemcitabine, platinum or paclitaxel regimen in adjuvant or neoadjuvant chemotherapy;
5. Adequate organ function was required, as evidenced by absolute neutrophil count ≥ 1.5 x 109 /L, platelet count ≥ 100 x109/L, hemoglobin ≥ 90 g/L (9 g/dL);
6. hepatic enzyme levels ≤ 2.5 x the upper limit of the normal range (ULN), alkaline phosphatase levels ≤ 5.0 x the ULN, total bilirubin levels ≤ 1.5 x the ULN, and serum creatinine levels ≤1.5 mg/dL (or creatinine clearance ≥50 mL/min);
7. Previous radiotherapy was allowed if it involved \<25% of bone marrow and was completed 4 weeks before study entry; Patients must be recovered from acute toxicity before the clinical trials;
8. Pregnancy test: negative (female only); Women with fertility need pregnancy test (serum or urine) in 7 days before entering the group and the results were negative. Male or female patients with reproduction potential had to use an approved contraceptive method during and for 8 weeks after the end of study treatment.
9. Patients are judged by researcher to be the compliance of research requirements and follow-up.
10. All the patients provided their written informed consent before enrollment.
11. The standard first-line platinum-based regimens according to the clinical practice, and the efficacy was evaluated every two cycles.
Exclusion Criteria
1. EGFR positive or ALK positive (patients, the status of EGFR and ALK were unknown due to the detection, were included);
2. Participation in any clinical research in 4 weeks before the first dosage, except non interventional epidemiological investigation;
3. Patients with the complications in high risk;
4. Primary brain tumors or central nervous system (CNS) metastatic carcinoma. The patients who are suspected the CNS metastatic carcinoma should be scanned in 28 days before entering the group. Other malignant disease five years ago (except cone-biopsied carcinoma-in-situ of the cervix or adequately treated basal or squamous cell carcinoma of the skin)
5. Third-space fluid collection that has the clinical significance, such as ascites or pleural effusion, cannot control through the drainage or other method;
6. Serious mental retardation or cognitive impairment, psychotic illness, poor compliance, cannot meet and narrate therapy responders;
7. No eliminated acute or chronic infection, or other serious concomitant diseases;
8. Serious or uncontrolled concomitant disorders (active infection, ischemic heart diseases, arrhythmia, liver dysfunction, or peripheral nerve disorder);
9. Patients with bleeding tendency or organ transplant;
10. Alcohol or drug dependent patients; patients with the chronic administration of adrenal cortical hormone or immunosuppressive; patients with AIDS or other infectious diseases;
11. Active hepatitis, liver metastasis is over 3/4 of the whole liver;
12. A history of drug allergy;
13. The female patients in the reproductive years are unwilling contraception;
14. Accept other anti-tumor therapy at the same time;
15. The researchers believe that the patients are not able to complete the entire clinical trial.
2. Participation in any clinical research in 4 weeks before the first dosage, except non interventional epidemiological investigation;
3. Patients with the complications in high risk;
4. Primary brain tumors or central nervous system (CNS) metastatic carcinoma. The patients who are suspected the CNS metastatic carcinoma should be scanned in 28 days before entering the group. Other malignant disease five years ago (except cone-biopsied carcinoma-in-situ of the cervix or adequately treated basal or squamous cell carcinoma of the skin)
5. Third-space fluid collection that has the clinical significance, such as ascites or pleural effusion, cannot control through the drainage or other method;
6. Serious mental retardation or cognitive impairment, psychotic illness, poor compliance, cannot meet and narrate therapy responders;
7. No eliminated acute or chronic infection, or other serious concomitant diseases;
8. Serious or uncontrolled concomitant disorders (active infection, ischemic heart diseases, arrhythmia, liver dysfunction, or peripheral nerve disorder);
9. Patients with bleeding tendency or organ transplant;
10. Alcohol or drug dependent patients; patients with the chronic administration of adrenal cortical hormone or immunosuppressive; patients with AIDS or other infectious diseases;
11. Active hepatitis, liver metastasis is over 3/4 of the whole liver;
12. A history of drug allergy;
13. The female patients in the reproductive years are unwilling contraception;
14. Accept other anti-tumor therapy at the same time;
15. The researchers believe that the patients are not able to complete the entire clinical trial.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Association of Clinical Trials
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yi-Long Wu
MD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
Guangzhou, Guangdong, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Haiyan Tu, MD
Role: primary
Yi-Long Wu, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013 Mar 10;31(8):1039-49. doi: 10.1200/JCO.2012.45.3753. Epub 2013 Feb 11.
Reference Type
BACKGROUND
Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007 Dec;98(12):1817-24. doi: 10.1111/j.1349-7006.2007.00607.x. Epub 2007 Sep 20.
Reference Type
BACKGROUND
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 Aug 2;448(7153):561-6. doi: 10.1038/nature05945. Epub 2007 Jul 11.
Reference Type
BACKGROUND
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. doi: 10.1056/NEJMoa011954.
Reference Type
BACKGROUND
Hoang T, Dahlberg SE, Schiller JH, Johnson DH. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Lung Cancer. 2013 Jul;81(1):47-52. doi: 10.1016/j.lungcan.2013.03.018. Epub 2013 Apr 21.
Reference Type
BACKGROUND
Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24. doi: 10.1200/JCO.2003.12.046. Epub 2003 Jul 1.
Reference Type
BACKGROUND
Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, Aitini E, Carteni G, Riska H, Tsai YH, Abratt R. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2009 Jul;20(7):1249-56. doi: 10.1093/annonc/mdn774. Epub 2009 Mar 10.
Reference Type
BACKGROUND
Yang JJ, Zhou Q, Liao RQ, Huang YS, Xu CR, Wang Z, Wang BC, Chen HJ, Wu YL. Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial. Chin J Cancer Res. 2012 Jun;24(2):97-102. doi: 10.1007/s11670-012-0097-8.
Reference Type
BACKGROUND
Teramoto K, Asada Y, Ozaki Y, Suzumura Y, Nakano Y, Sawai S, Tezuka N, Inoue S, Fujino S. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer. Cancer Chemother Pharmacol. 2012 Oct;70(4):531-7. doi: 10.1007/s00280-012-1941-8. Epub 2012 Aug 5.
Reference Type
BACKGROUND
Naito Y, Kubota K, Ohmatsu H, Goto K, Niho S, Yoh K, Ohe Y. Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung. Ann Oncol. 2011 Nov;22(11):2471-2475. doi: 10.1093/annonc/mdq781. Epub 2011 Mar 4.
Reference Type
BACKGROUND
Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R, Saito H. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003 Jul;52(1):73-8. doi: 10.1007/s00280-003-0615-y. Epub 2003 May 16.
Reference Type
BACKGROUND
Shirai T, Hirose T, Noda M, Ando K, Ishida H, Hosaka T, Ozawa T, Okuda K, Ohnishi T, Ohmori T, Horichi N, Adachi M. Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer. Lung Cancer. 2006 May;52(2):181-7. doi: 10.1016/j.lungcan.2006.01.004. Epub 2006 Mar 24.
Reference Type
BACKGROUND
Sznol M. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J. 2014 Jul-Aug;20(4):290-5. doi: 10.1097/PPO.0000000000000056.
Reference Type
BACKGROUND
Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004 Aug 1;10(15):5094-100. doi: 10.1158/1078-0432.CCR-04-0428.
Reference Type
BACKGROUND
Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18.
Reference Type
BACKGROUND
Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015 Apr;3(4):326-32. doi: 10.1158/2326-6066.CIR-14-0133. Epub 2014 Dec 19.
Reference Type
BACKGROUND
Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, Sage EH. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 2003 Sep 1;63(17):5376-80.
Reference Type
BACKGROUND
Kurtul N, Eroglu C, Unal D, Tasdemir EA, Orhan O, Zararsiz G, Baran M, Kaplan B, Kontas O. Prognostic value of SPARC expression in unresectable NSCLC treated with concurrent chemoradiotherapy. Asian Pac J Cancer Prev. 2014;15(20):8911-6. doi: 10.7314/apjcp.2014.15.20.8911.
Reference Type
BACKGROUND
Huang Y, Zhang J, Zhao YY, Jiang W, Xue C, Xu F, Zhao HY, Zhang Y, Zhao LP, Hu ZH, Yao ZW, Liu QY, Zhang L. SPARC expression and prognostic value in non-small cell lung cancer. Chin J Cancer. 2012 Nov;31(11):541-8. doi: 10.5732/cjc.012.10212. Epub 2012 Oct 10.
Reference Type
BACKGROUND
Kato T, Miyamoto M, Kato K, Cho Y, Itoh T, Morikawa T, Okushiba S, Kondo S, Ohbuchi T, Katoh H. Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Lett. 2004 Oct 8;214(1):121-8. doi: 10.1016/j.canlet.2004.04.017.
Reference Type
BACKGROUND
Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, Shay JW, Gazdar AF, Minna JD. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 2004 Jun 15;64(12):4277-85. doi: 10.1158/0008-5472.CAN-03-3941.
Reference Type
BACKGROUND
Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008 Jan;59(1):105-10. doi: 10.1016/j.lungcan.2007.07.024. Epub 2007 Sep 11.
Reference Type
BACKGROUND
Chen D, Shen C, Du H, Zhou Y, Che G. Duplex value of caveolin-1 in non-small cell lung cancer: a meta analysis. Fam Cancer. 2014 Sep;13(3):449-57. doi: 10.1007/s10689-014-9707-6.
Reference Type
BACKGROUND
Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011 Feb;12(2):175-80. doi: 10.1016/S1470-2045(10)70087-5.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTONG1501
Identifier Type: -
Identifier Source: org_study_id